Acacia Pharma swaps debt for equity investment by Cosmo

1 June 2020

Shares of Cambridge, UK-based Acacia Pharma (Euronext: ACPH) were up 7.4% at 3.21 euros by mid-morning today, after it announced an amendment to the terms of its loan agreement with Italy’s Cosmo Pharmaceuticals (SIX: COPN).

Under the terms of the amendment, the 10 million-euro ($11.1 million) loan facility that was made available on the approval of Barhemsys (amisulpride injection) is terminated and replaced with a 10 million-euro equity investment at a price of 3.112 euros per share, which represents an around 4.1% premium to the closing share price on May 29, 2020 and equates to 3,213,769 shares to be issued to Cosmo.

In addition, a further 367,893 shares are being issued to Cosmo (at an equity subscription price of 2.99 euros per share) in satisfaction of a 1 million-euro break fee payable under the terms of the loan amendment. The 25 million-euro loan facility, which will be made available by Cosmo on the approval of Byfavo (intravenous remimazolam), has not been affected by this transaction.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK